Ebvaciclib
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].
Product Specifications
CAS Number
2185857-97-8
Product Name Alternative
PF-06873600
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-06873600.html
Purity
99.98
Solubility
DMSO : 83.33 mg/mL (ultrasonic)
Smiles
O=C1N([C@H]2[C@](O)(CCC2)C)C3=NC(NC4CCN(CC4)S(C)(=O)=O)=NC=C3C=C1C(F)F
Molecular Formula
C20H27F2N5O4S
Molecular Weight
471.52
Precautions
H302, H315, H319, H335
References & Citations
[1]US 2018/0044344 A1.|[2]NCI Drug Dictionary
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK2; CDK4; CDK6
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
